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Introduction
In patients receiving anticancer chemotherapy, one 
of the most troublesome side effects is chemotherapy-
induced nausea and vomiting (CINV). Persistent CINV 
can lead to dehydration, electrolyte abnormalities, and 
undernutrition, along with deterioration of the patient’s 
physical and mental state, and it often becomes difficult 
to continue chemotherapy. Thus, preventing or alleviating 
the symptoms of CINV is important both to maintain the 
quality of life and to allow continuation of chemotherapy 
in cancer patients.
The oral neurokinin-1 receptor antagonist aprepitant 
is an antiemetic drug with a new mechanism of action 
that not only shows efficacy for acute CINV (within 24 
hours of starting chemotherapy) but also for delayed 
CINV (24 hours or more after starting chemotherapy), 
which is poorly controlled by current therapies, and the 
efficacy of aprepitant against the emetic effect of single-
dose cisplatin has been demonstrated (Roila et al., 2010; 
Basch et al., 2011).
We employ a daily cisplatin regimen (FP therapy with 
daily administration of cisplatin at 20mg/m2 from Day 1 to 
Day 4 and 5-fluorouracil (5-FU) at 400 mg/m2 from Day 
1 to Day 5) (Brizel et al., 1998) to treat patients with head 
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Abstract
 Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has 
been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist 
during daily administration of cisplatin. Accordingly, we investigated the efficacy and safety of aprepitant in 
patients with head and neck cancer (HNC) receiving combination therapy with cisplatin and 5-FU (FP therapy). 
Materials and Methods: Twenty patients with HNC were prospectively studied who received a triple antiemetic 
regimen comprising granisetron (40μg/kg on Days 1-4), dexamethasone (8 mg on Days 1-4), and aprepitant (125 
mg on day 1 and 80mg on days 2-5) with FP therapy (cisplatin 20 mg/m2 on days 1-4; 5-FU 400 mg/m2 on days 
1-5) (aprepitant group). We also retrospectively studied another 20 HNC patients who received the same regimen 
except for aprepitant (control group). Results: For efficacy endpoints based on nausea, the aprepitant group 
showed significantly better results, including a higher rate of complete response (no vomiting and no salvage 
therapy) for the acute phase (p=0.0342), although there was no marked difference between the two groups with 
regard to percentage of patients in whom vomiting was suppressed. There were no clinically relevant adverse 
reactions to aprepitant. Conclusions: This study suggested that a triple antiemetic regimen containing aprepitant 
is safe and effective for HNC patients receiving daily cisplatin therapy. 
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and neck cancer (HNC), but there have been few studies 
on the efficacy of aprepitant during daily administration 
of cisplatin and no specific antiemetic regimen for daily 
cisplatin therapy has been established (Roila et al., 2010; 
Basch et al., 2011; Einhorn et al., 2011). When FP therapy 
is performed at our department, severe nausea tends to 
occur on or after the last day of cisplatin administration 
and it has a strong impact on quality of life (Sun et al., 
2005). There have been several other reports that CINV is 
most severe on Day 4 or Day 5 during daily administration 
of cisplatin (Einhorn et al., 2007; Jordan et al., 2009; 
Roila et al., 2010; Einhorn et al., 2011), suggesting that a 
new regimen for use of aprepitant during daily cisplatin 
administration should be established (Ellebaek and 
Herrstedt, 2008; Roila et al., 2010).
When cisplatin is administered for 4 days, the 
incidence of CINV is expected to peak around Day 4 or 
later. Although aprepitant is usually administered for 3 
days, this would not adequately control CINV associated 
with 4 days of cisplatin therapy that occurs on Day 5 or 
later. Therefore, aprepitant was administered for 5 days 
in the present prospective investigation into the effects 
of aprepitant in HNC patients receiving cisplatin therapy, 
with a focus on nausea. The results of this study were 
expected to provide useful data about the influence of 
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Patients were eligible for this study if they had HNC 
and were scheduled to start their first course of FP therapy 
(cisplatin at 20mg/m2 from Day 1 to Day 4 and 5-FU at 
400mg/m2 from Day 1 to Day 5), if they had not previously 
received moderately or severely emetic chemotherapy, and 
if their Eastern Cooperative Oncology Group performance 
status was 0-2.
Exclusion criteria were as follows: (1) serious hepatic 
or renal disease, (2) nausea or vomiting within 24 hours 
before the start of chemotherapy, (3) use of antiemetic 
drugs within 48 hours before the start of chemotherapy, 
(4) any factor that could cause nausea or vomiting 
other than chemotherapy (e.g., brain tumor/metastasis, 
intestinal obstruction, or active peptic ulcer), (5) scheduled 
abdominal irradiation, and (6) any other reason that led 
the attending doctor to conclude that the patient was not 
eligible.
In the aprepitant group, 20 patients were studied 
prospectively from May 2010 to June 2012. In the control 
group, 20 other patients treated from May 2009 to April 
2010 were studied retrospectively. All of the patients 
started their first course of a regimen involving daily 
administration of cisplatin at 20 mg/m2.
Study treatment
Patients in the aprepitant group were administered the 
drug once a day at a dose of 125mg on Day 1 and 80mg 
on Days 2 to 5. They also received granisetron (a 5-HT3 
receptor antagonist) intravenously at 40μg/kg once a day 
on Days 1 to 4 and dexamethasone intravenously at 8 mg 
once a day on Days 1 to 4 (Table 1). In the control group, 
granisetron and dexamethasone were administered by the 
same regimens as mentioned above (Table 1).
Evaluation of efficacy
Evaluation of efficacy was performed over an 8-day 
period from the first day of cisplatin therapy to 4 days 
after completing cisplatin administration. Within that 
period, vomiting on Days 1 to 4 was defined as acute 
and vomiting on Days 5 to 8 was defined as delayed. 
Patients in the aprepitant group received a diary to 
record CINV and salvage therapy for the 8-day study 
period with each course of chemotherapy. In the control 
group, information about CINV and salvage therapy was 
collected retrospectively from the medical records of 20 
other patients.
The primary endpoint of this study was the percentage 
of patients (courses) with a complete response (CR, 
defined as no vomiting and no salvage therapy) in the 
entire 8-day period, the acute phase (Days 1-4), and the 
delayed phase (Days 5-8). Secondary endpoints were as 
follows: i) the percentage of patients (courses) with only 
mild nausea (no vomiting, no salvage therapy, and no 
moderate/severe nausea) during the overall 8-day period, 
the acute phase, and the delayed phase; ii) the percentage 
of patients (courses) with total control of nausea (no 
vomiting, no salvage therapy, and no nausea) during the 
overall period, the acute phase, and the delayed phase; 
iii) the percentage of patients (courses) without nausea 
during the overall period, the acute phase, and the delayed 
phase; and iv) the percentage of patients (courses) without 
vomiting during the overall period, the acute phase, and 
the delayed phase.
Each patient in the prospective study evaluated the 
severity of nausea once a day by classifying it into the 
following 4 categories: no nausea, mild nausea (eating and 
drinking were possible despite nausea), moderate nausea 
(drinking fluids was possible, but not eating), and severe 
nausea (neither eating nor drinking was possible). The 
subjects recorded these evaluations in their patient diaries. 
The patients in the prospective study also recorded the time 
of each episode of vomiting in the diary. If consecutive 
vomiting episodes occurred within 1 minute, these were 
classified as a single event.
The attending doctor and the patient recorded the 
details of salvage therapy in the medical record and the 
patient diary, respectively. Salvage therapy was only 
provided to alleviate nausea and/or vomiting at the request 
of the patient and was not provided prophylactically.
Statistical analysis
The efficacy evaluations for each course were 
combined and comparison was performed between the 
two groups by using the chi-square test. The level of 
significance was set at p=0.05.
Ethical considerations
This study was approved by the Ethics Committee 
of Nagasaki University Hospital and was performed in 
accordance with the standards laid down in the 1964 
Declaration of Helsinki. All of the subjects gave written 
informed consent to participation in the study.
Results 
Clinical characteristics of the subjects are shown 
in Table 2. There were no marked differences of these 
characteristics between the aprepitant group and the 
control group. The CR rate for the overall study period 
(Days 1 to 8), which was the primary endpoint, is shown 
Table 1. Antiemetic Medications
 Drug Day 1 Day 2 Day 3 Day 4 Day 5
Aprepitant group Aprepitant (p.o.) 125 mg 80 mg 80 mg 80 mg 80 mg
 Dexamethasone (i.v.) 8 mg 8 mg 8 mg 8 mg Not administered
 Granisetron (i.v.) 40 mg/kg 40 mg/kg 40 mg/kg 40 mg/kg Not administered
Control group Dexamethasone (i.v.) 8 mg 8 mg 8 mg 8 mg Not administered
 Granisetron (i.v.) 40 mg/kg 40 mg/kg 40 mg/kg 40 mg/kg Not administered
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in Figure 1, as well as the CR rate and the percentage 
of patients (courses) without vomiting during the acute 
phase (Days 1 to 4) and the delayed phase (Days 5 to 8) 
(secondary endpoints). There was no significant difference 
between the groups with respect to the CR rate for the 
overall period and the delayed phase, but the CR rate 
during the acute phase was significantly higher in the 
aprepitant group (p=0.0342). The percentage of patients 
(courses) with complete protection, total control, no 
nausea, and no vomiting (secondary endpoints) is shown 
in Figure 2a-d, respectively.
The two groups showed no significant differences 
with regard to the percentage of patients (courses) without 
vomiting in any of the 3 evaluation periods. However, 
fewer patients in the aprepitant group had vomiting during 
the overall period and acute phase when compared with 
the control group. Regarding patients with complete 
protection, total control, and no nausea, results were 
significantly better in the aprepitant group for the overall 
study period, acute phase, and delayed phase. Regarding 
safety, no clinically important side effects occurred in the 
aprepitant group during the observation period.
Discussion
In this study, administration of aprepitant led to marked 
suppression of nausea induced by daily administration 
of cisplatin. In many previous studies on the daily 
administration of cisplatin, steroids were administered 
until around Day 8 (Ellebaek and Herrstedt, 2008; 
Jordan et al., 2009; Albany et al., 2012). However, we 
administered aprepitant from Day 1 to Day 5 as antiemetic 
therapy together with a 5-HT3 receptor antagonist and 
a steroid from Day 1 to Day 4. With a single dose of 
cisplatin, the day of administration (Day 1) is defined as 
the acute phase, and Days 2 onward are defined as the 
delayed phase. However, daily administration of cisplatin 
(a highly emetic drug) causes overlapping nausea and/or 
vomiting in the acute and delayed phases (Ellebaek and 
Herrstedt, 2008; Jordan et al., 2009). In the present study, 
we defined the period from Day 1 to Day 4 (duration of 
cisplatin administration) as the acute phase and the period 
from Day 5 to Day 8 as the delayed phase. 
Aprepitant showed efficacy against nausea in the 
overall study period as well as the acute phase and the 
delayed phase. However, the possibility that the overall 
efficacy was due to the carry-over effect of aprepitant 
(its antiemetic effect may be carried over to subsequent 
courses) cannot be ruled out. In this study, there was no 
significant difference of the CR rate and vomiting in the 
overall study period and the delayed phase, which was 
because there were also patients with vomiting in the 
control group. Further improvement in the control of 
CINV is needed. Possible measures include prolonging 
the administration period of aprepitant (Jordan et al., 
2009), prolonging administration of steroids (Jordan et 
al., 2009), combined use of palonosetron (Einhorn et al., 
2007), and administration of aprepitant on Day 3 and 
later days (Albany et al., 2012). Xiao et al. (2014) also 
suggested recently that CINV after highly emetogenic 
chemotherapy may be prevented by the use of an electronic 
anti-nausea instrument with hydrochloride palonosetron 
Figure 1. CR Rate There was no Significant Difference 
between the Two Groups with Respect to the CR Rate 
for the Overall Study Period (Days 1 to 8) and the 
Delayed Phase (Days 5 to 8), but the CR Rate During 
the Acute Phase (Days 1 to 4) was Significantly Higher 
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Table 2. Patient Characteristics
 Aprepitant group Control group P value
 Number 20 20 
 Total no. of courses 50 50 
 Men:Women 17.03 17.03 1.0000a
 Mean age 59.9±7.22 65.7±6.94 0.0135b
Stage   
 I 0 1 0.5153c
 II 4 1 
 III 3 1 
 IV 13 15 
Performance status   
 0 18 15 0.4075a
 1 2 5 
aFisher’s exact test; bt-test; cchi-square test
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(Xiao et al., 2014).
In the present study, the percentage of patients without 
nausea in the aprepitant group during the overall study 
period, acute phase, and delayed phase was 72.3%, 80.8%, 
and 72.9%, respectively. In a study conducted by Jordan 
et al., aprepitant was administered from Day 1 until 2 
days after completing administration of highly emetic 
anticancer drugs (an average of 5.5 days and maximum of 
7 days) and dexamethasone (8mg/day) was administered 
during chemotherapy and for 2 days afterward, and the 
percentage of patients without nausea during the overall 
study period, acute phase, and delayed phase was 76.3%, 
78.9%, and 78.9%, respectively (Jordan et al., 2009). In 
that study, the chemotherapy administration period was 
longer and the mean age of the patients was younger than 
in our study (the mean age was 43 years versus 59.9 years). 
Accordingly, prolonged administration of aprepitant and 
steroids could be expected to achieve further improvement 
of nausea (Jordan et al., 2009). Einhorn et al. administered 
palonosetron (Days 1, 3, and 5) and dexamethasone (20 
mg on Days 1-2, 8mg on Days 6-7, and 4mg on Day 8) 
during daily cisplatin therapy for 5 days, and reported 
good control of nausea (Einhorn et al., 2007). Albany et 
al. conducted a phase III clinical trial in patients receiving 
daily cisplatin for 5 days to treat germ cell tumors that 
compared a group with oral aprepitant from Day 3 to Day 
7 and a group with oral placebo from Day 3 to Day 7 
(dexamethasone was administered at 20mg on Days 1 and 
2 in both groups, and then at mg in the aprepitant group 
and at 8 mg in the placebo group from Day 6 to Day 8). 
The nausea rate (evaluated on a visual analog scale) was 
lower in the aprepitant group, but there was no significant 
difference between the two groups (Albany et al., 2012). 
Compared with these studies, we administered a lower 
steroid dose for a shorter period in our study. Thus, altering 
the dosage of steroids and use of palonosetron may further 
improve CINV.
The present study has several limitations. The first 
limitation relates to the comparison between two arms 
whose data were collected in different fashion, with one 
in a prospective setting and the other had data collected 
retrospectively. Hence, caution is needed in interpreting 
the findings. Although we utilized patient diaries to ensure 
that minor CINV episodes (easily missed in routine 
assessment) were recorded, it was impossible to fully 
exclude the possibility of overestimating the efficacy of 
aprepitant. There may also be between-group differences 
in terms of patient education about prophylactic therapy. 
This is relevant because nausea has been regarded 
as a “neuropsychic” experience, and the manner in 
which patients are informed could influence outcomes, 
independent of drug action. Second, the sample size of the 
present study was not large enough to draw a definitive 
conclusion. Further research with larger prospective 
cohorts is warranted.
Nevertheless, this study suggested the usefulness 
of aprepitant for suppressing CINV during daily 
administration of cisplatin, a highly emetic anticancer 
agent. 
References
Albany C, Brames MJ, Fausel C, et al (2012). Randomized, 
double-blind, placebo-controlled, phase III cross-over 
study evaluating the oral neurokinin-1 antagonist aprepitant 
in combination with a 5HT3 receptor antagonist and 
dexamethasone in patients with germ cell tumors receiving 
5-day cisplatin combination chemotherapy regimens: a 
hoosier oncology group study. J Clin Oncol, 30, 3998-4003.
Basch E, Prestrud AA, Hesketh PJ, et al (2011). Antiemetics: 
American Society of Clinical Oncology clinical practice 
guideline update. J Clin Oncol, 29, 4189-98.
Brizel DM, Albers ME, Fisher SR, et al (1998). Hyperfractionated 
irradiation with or without concurrent chemotherapy for 
locally advanced head and neck cancer. N Engl J Med, 338, 
1798-804.
Einhorn LH, Brames MJ, Dreicer R, et al (2007). Palonosetron 
plus dexamethasone for prevention of chemotherapy-
induced nausea and vomiting in patients receiving multiple-
day cisplatin chemotherapy for germ cell cancer. Support 
Care Cancer, 15, 1293-300.
Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P 
(2011). Antiemetic therapy for multiple-day chemotherapy 
and additional topics consisting of rescue antiemetics and 
high-dose chemotherapy with stem cell transplant: review 
and consensus statement. Support Care Cancer, 1, 1-4.
Ellebaek E, Herrstedt J (2008). Optimizing antiemetic therapy 
in multiple-day and multiple cycles of chemotherapy. Curr 
Opin Support Palliat Care, 2, 28-34.
Jordan K, Kinitz I, Voigt W, et al (2009). Safety and efficacy of 
a triple antiemetic combination with the NK-1 antagonist 
aprepitant in highly and moderately emetogenic multiple-day 
chemotherapy. Eur J Cancer, 45, 1184-7.
Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update 
for MASCC and ESMO in the prevention of chemotherapy- 
and radiotherapy-induced nausea and vomiting: results of 
the Perugia consensus conference. Ann Oncol, 5, 232-43.
Sun CC, Bodurka DC, Weaver CB, et al (2005). Rankings and 
symptom assessments of side effects from chemotherapy: 
insights from experienced patients with ovarian cancer. 
Support Care Cancer, 13, 219-27.
Xiao Y, Liu J, Liu YC, et al. (2014). Phase II study on EANI 
combined with hydrochloride palonosetron for prevention 
of chemotherapy-induced nausea and vomiting following 
highly emetogenic chemotherapy. Asian Pac J Cancer Prev, 
15, 3951-4.
